[Study of the effects of a new vitamin D3 derivative on type II collagen-induced arthritis in an experimental rat model of rheumatoid arthritis].
The effects of a new derivative of vitamin D3, 22-oxa-1 alpha,25-dihydroxyvitamin D3 (OCT), on rheumatoid arthritis was investigated using collagen-induced arthritis in rat, as an experimental model of the disease. Peroral administration of OCT significantly suppressed the incidence of arthritis and inhibited hind-paw-swelling. The levels of IgM and IgG antibodies against Type II collagen in sera were found to decrease in the OCT treated-group. The production of immunoglobulin against Type II collagen from rat spleen cells was also decreased in this group. These immunological effects of OCT on collagen-induced arthritis were more remarkable than those of 1 alpha-hydroxyvitamin D3. These findings indicated that OCT may have a therapeutic value as an immunoregulatory agent for patients with rheumatoid arthritis through inhibition of the autoimmune response to Type II collagen.
Kitamura
A
A
Department of Orthopaedic Surgery, Jikei University School of Medicine, Tokyo, Japan.
D000284:Administration, Oral; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000209:etiology / Q000276:immunology* / Q000473:pathology; D001323:Autoantibodies / Q000097:blood; D001835:Body Weight / Q000187:drug effects; D002117:Calcitriol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003094:Collagen / Q000276:immunology*; D004195:Disease Models, Animal; D008297:Male; D051381:Rats; D011917:Rats, Inbred Lew
D001323:Autoantibodies; D003094:Collagen; D002117:Calcitriol; C051883:maxacalcitol